Just wanted to move this discussion over to the Zenith Board. San Fran posted on the RVX board a message entitled "What Are Our Reasonable Expectations" regarding the upcoming Zenith ZEN-3694 prostate cancer trial and its timeline and effect on valuation. Here is my response, also copied below.

-------------------------------------------------------------------------------

In addition to what Hartland said, we bascially have two things to go off of right now. Masila's unofficial transcript of the January AGM and the Corporate Update slides.

The patients in this trial have already gone through or become resistant to chemo or other drugs. Patients in this Phase 1 trial won't be taking placebo, so they’ll be able to see in Phase 1 whether ZEN-3694 is working or not. Hopefully they start this quarter, but if not sounds like sometime H1 2016. In either case, they start out at low dose and then about every month double the dose. By the third dosing, they are hoping to see some activity/efficacy by whether the patients are surviviing or not. So safety and efficacy are somewhat confirmed at the same time. So depending on the trial start date and enrollment, they could have some strong data by summer 2016. However, I believe this estimate was based upon a Q1 2016 start date. After this first cohort, they then plan to do a second cohort that will be in combination with enzalutamide to show drug synergy. This may also occur in 2016. Then in 2017, their plan is to take the same drug and start working in expansion cohorts such as other solid tumors (i.e. breast cancer) as well as hematological malignancies.

BearDownAZ